AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8722747 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of breast cancer in first-degree relatives with onset at or before age 45
Number of subjects: 41837
Study 8722747 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of breast cancer in first-degree relatives with onset after age 45
Number of subjects: 41837
Study 8722747 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of prostate cancer in first-degree relatives
Number of subjects: 41837
Study 1818543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA) (n = 25)
Number of subjects: 52
Study 1818543 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) (n = 27)
Number of subjects: 52
Study 7059325 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Air Force (CAF) protocol with a constant speed of 3.5 mph and a 5% increase in elevation every 3 min
Number of subjects: 24
Study 7059325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 24
Study 7059325 — intervention group
Group type: EXPERIMENTAL
Intervention: Balke protocol
Number of subjects: 24
Study 7059325 — intervention group
Group type: COMPARATOR
Intervention: All five protocols
Number of subjects: 24
Study 29903473 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Formula 1 (EF1; 43% of total palmitate at sn‐2; n = 166)
Number of subjects: 488
Study 29903473 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Formula 2 (EF2; 51% of total palmitate at sn‐2; n = 160)
Number of subjects: 488
Study 29903473 — intervention group
Group type: COMPARATOR
Intervention: Control Formula (CF; 16% of total palmitate at sn‐2; n = 162)
Number of subjects: 488
Study 29215191 — intervention group
Group type: EXPERIMENTAL
Intervention: Team‐Game Tournament
Number of subjects: 52
Study 29215191 — intervention group
Group type: EXPERIMENTAL
Intervention: Jigsaw
Number of subjects: 52
Study 26542420 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 97
Study 26542420 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 97
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting blood glucose
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised fasting blood glucose or currently on medication for diabetes
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in men
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in women
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in rural areas
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in urban areas
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in males in rural areas
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in males in urban areas
Number of subjects: 3056
Study 24884894 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to previous estimates
Number of subjects: 3056
Study 22415888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300mg plus Losartan 100mg daily for 36 weeks
Number of subjects: 465
Study 22415888 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100mg daily for 36 weeks
Number of subjects: 465
Study 19855266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 70
Study 19855266 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 70
Study 19855266 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 at-risk subjects)
Number of subjects: 70
Study 18049253 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1
Number of subjects: 0
Study 18049253 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2
Number of subjects: 0
Study 18049253 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 3
Number of subjects: 0
Study 16318744 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 36
Study 16318744 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 36
Study 12097848 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (BR1) at a dose of 1.2 ml
Number of subjects: 113
Study 12097848 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (BR1) at a dose of 2.4 ml
Number of subjects: 113
Study 12097848 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (BR1) at doses of 0.3, 0.6, 1.2, and 2.4 ml
Number of subjects: 113
Study 12097848 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (BR1)
Number of subjects: 113
Study 9922304 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 120
Study 9922304 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 120
Study 9922304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9922304 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori presence
Number of subjects: 120
Study 7586113 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 20)
Number of subjects: 41
Study 7586113 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg.kg‐1 alone (n = 21)
Number of subjects: 41
Study 2275907 — intervention group
Group type: COMPARATOR
Intervention: 3% 2‐chloroprocaine (C)
Number of subjects: 84
Study 2275907 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine (L)
Number of subjects: 84
Study 2275907 — intervention group
Group type: COMPARATOR
Intervention: 1.5% mepivacaine (M)
Number of subjects: 84
Study 30416189 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group (n=81)
Number of subjects: 414
Study 30416189 — intervention group
Group type: COMPARATOR
Intervention: No statin group (n=333)
Number of subjects: 414
Study 29901598 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block using ropivacaine 0.25% 10 mL including dexamethasone 5 mg
Number of subjects: 44
Study 29901598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interscalene block)
Number of subjects: 44
Study 29901598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (postoperative pulmonary function tests)
Number of subjects: 44
Study 26749187 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° counterclockwise rotation (CCR) of the endotracheal tube (ETT)
Number of subjects: 60
Study 26749187 — intervention group
Group type: COMPARATOR
Intervention: Standard bevel direction (facing left)
Number of subjects: 60
Study 24768112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 417
Study 24768112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 24768112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 417
Study 22325115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical 2% lidocaine gel
Number of subjects: 200
Study 22325115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 20455705 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12 mg for women, 15 mg for men) for 18 months
Number of subjects: 231
Study 20455705 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 231
Study 17039265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential doxorubicin 75 mg/M2 q2 wks x 3 and docetaxel 40 mg/M2 weekly x 6
Number of subjects: 70
Study 17039265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 70
Study 17039265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression in IBC
Number of subjects: 70
Study 17039265 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX Recurrence Score
Number of subjects: 70
Study 15752394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.1 mg kg(‐1))
Number of subjects: 66
Study 15752394 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg kg(‐1))
Number of subjects: 66
Study 15752394 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg kg(‐1))
Number of subjects: 66
Study 12045510 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroreflexotherapy intervention
Number of subjects: 104
Study 12045510 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (Control)
Number of subjects: 104
Study 9447860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10
Study 9447860 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 8535577 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0
Study 2146060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (twice a day)
Number of subjects: 100
Study 2146060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (twice a day)
Number of subjects: 100
Study 2146060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (once a day)
Number of subjects: 100
Study 2146060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once a day)
Number of subjects: 100
Study 2146060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (once a day)
Number of subjects: 100
Study 509955 — intervention group
Group type: EXPERIMENTAL
Intervention: GravigardR (commercially available Cu-7-IUD)
Number of subjects: 516
Study 509955 — intervention group
Group type: COMPARATOR
Intervention: Cu-7-Nullip (small-sized Cu-7-IUD for nulliparous women)
Number of subjects: 516
Study 509955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GravigardR and Cu-7-Nullip
Number of subjects: 516
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized stigma scale for PLHIV
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare settings stigma measure for PLHIV
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear and judgement scale for community members
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stigma in the community scale for community members
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stigma in healthcare settings scale for community members
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear and judgement scale for health workers
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stigma in the community scale for health workers
Number of subjects: 11395
Study 31840400 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived co-worker stigma in healthcare settings scale for health workers
Number of subjects: 11395
Study 27989952 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 0
Study 25331853 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle interventions (diet and exercise recommendations)
Number of subjects: 2186
Study 23635771 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours of sleep deprivation with psychological stress
Number of subjects: 23
Study 23635771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sleep deprivation)
Number of subjects: 23
Study 21372740 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133 cells from bone marrow (group A)
Number of subjects: 15
Study 21372740 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133 cells from peripheral blood (group B)
Number of subjects: 15
Study 21372740 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy alone (group C)
Number of subjects: 15
Study 18241712 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal temperature‐controlled radiofrequency tissue volume reduction (TCRFTVR)
Number of subjects: 30
Study 18241712 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection with microdebrider (SMRM)
Number of subjects: 30
Study 18241712 — intervention group
Group type: COMPARATOR
Intervention: Both TCRFTVR and SMRM
Number of subjects: 30
Study 15960567 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16
Study 15960567 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16
Study 15960567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12001178 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 24
Study 12001178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12001178 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (in subgroup analysis)
Number of subjects: 24
Study 10497445 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (sIT) applied in 29 patients with pollinosis and 27 patients sensitive to house dust mite.
Number of subjects: 112
Study 10497445 — intervention group
Group type: COMPARATOR
Intervention: Routine pharmacotherapy alone (control group).
Number of subjects: 112
Study 10497445 — intervention group
Group type: COMPARATOR
Intervention: Laboratory workers with no history of atopy (control group).
Number of subjects: 112
Study 7481173 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-living (GL-group)
Number of subjects: 108
Study 7481173 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-group)
Number of subjects: 108
Study 1673097 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam with food
Number of subjects: 18
Study 1673097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam fasting
Number of subjects: 18
Study 7457560 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm format teaching aid
Number of subjects: 29
Study 7457560 — intervention group
Group type: COMPARATOR
Intervention: Prose form teaching aid
Number of subjects: 29
Study 31744319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg (SPARTAN only)
Number of subjects: 0
Study 31744319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study 31744319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0
Study 31744319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28975711 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal brow lift (TBL)
Number of subjects: 32
Study 28975711 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal browpexy (IBP)
Number of subjects: 32
Study 28655559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym-based exercise program for 12 months
Number of subjects: 0
Study 28655559 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program for 12 months with telephone follow-up for the first 10 weeks
Number of subjects: 0
Study 26631095 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg twice weekly with daily oral estrogen
Number of subjects: 70
Study 26631095 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice weekly with daily oral estrogen
Number of subjects: 70
Study 24548394 — intervention group
Group type: COMPARATOR
Intervention: Progynova only (Group A)
Number of subjects: 1072
Study 24548394 — intervention group
Group type: EXPERIMENTAL
Intervention: Progynova plus Femoston (Group B)
Number of subjects: 1072
Study 24548394 — intervention group
Group type: COMPARATOR
Intervention: Progynova only (2011 comparison)
Number of subjects: 1072
Study 20886631 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil or equivalent agents
Number of subjects: 35853
Study 19041049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (class III antiarrhythmic drug)
Number of subjects: 1518
Study 19041049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 16609032 — intervention group
Group type: EXPERIMENTAL
Intervention: l-selenomethionine (SeMet)
Number of subjects: 66
Study 16609032 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 66
Study 14724129 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain observation unit
Number of subjects: 972
Study 14724129 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 972
Study 11535875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (160 or 300 mg/day)
Number of subjects: 274
Study 9249636 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14
Study 9249636 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 14
Study 8213442 — intervention group
Group type: EXPERIMENTAL
Intervention: Teboroxime scanning
Number of subjects: 35
Study 8213442 — intervention group
Group type: COMPARATOR
Intervention: Redistribution imaging (thallium)
Number of subjects: 35
Study 8213442 — intervention group
Group type: EXPERIMENTAL
Intervention: Teboroxime imaging
Number of subjects: 35
Study 8213442 — intervention group
Group type: COMPARATOR
Intervention: Thallium reinjection scanning
Number of subjects: 35
Study 8213442 — intervention group
Group type: COMPARATOR
Intervention: Thallium reinjection
Number of subjects: 35
Study 3323604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 2
Study 3323604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) + Heparin
Number of subjects: 2
Study 3323604 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 2
Study 3323604 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine therapy
Number of subjects: 2
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior knowledge of blood pressure
Number of subjects: 145
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 145
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinalysis test
Number of subjects: 145
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 145
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosuria
Number of subjects: 145
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary healthcare sources
Number of subjects: 145
Study 30053863 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of herbal mixtures
Number of subjects: 145
Study 25863520 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness practice (Brief‐MP)
Number of subjects: 44
Study 25863520 — intervention group
Group type: COMPARATOR
Intervention: Control (sham meditation)
Number of subjects: 44
Study 24598496 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 80
Study 24598496 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with 2% chlorhexidine (CHX)
Number of subjects: 80
Study 22796948 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal replacers (MR, 190 kcal)
Number of subjects: 0
Study 22796948 — intervention group
Group type: COMPARATOR
Intervention: Yogurt (190 kcal)
Number of subjects: 0
Study 22796948 — intervention group
Group type: COMPARATOR
Intervention: Bagel with cream cheese and juice (400 kcal)
Number of subjects: 0
Study 22796948 — intervention group
Group type: COMPARATOR
Intervention: Hamburger with bun and soft drink (400 kcal)
Number of subjects: 0
Study 20399951 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced supply of emergency contraception (EC) pills with unlimited supply thereafter upon request
Number of subjects: 50
Study 20399951 — intervention group
Group type: COMPARATOR
Intervention: Routine postpartum contraceptive care (RCA)
Number of subjects: 50
Study 18599890 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 1700
Study 18599890 — intervention group
Group type: COMPARATOR
Intervention: CoStar stent
Number of subjects: 1700
Study 16162987 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee brace
Number of subjects: 42
Study 16162987 — intervention group
Group type: COMPARATOR
Intervention: Control (no bracing)
Number of subjects: 42
Study 12391107 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (Fi(O(2)) = 15.3%)
Number of subjects: 16
Study 12391107 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training (Fi(O(2)) = 20.9%)
Number of subjects: 16
Study 11022056 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 29
Study 8623181 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 503
Study 8623181 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 503
Study 8623181 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 503
Study 8445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (0.2 mg/day percutaneously)
Number of subjects: 9
Study 8445015 — intervention group
Group type: COMPARATOR
Intervention: Control (no estradiol treatment)
Number of subjects: 9
Study 3518730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg trimoprostil administered 30 min before meals
Number of subjects: 12
Study 3518730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg trimoprostil administered 30 min after meals
Number of subjects: 12
Study 3518730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29227962 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assisted structured aerobic exercise module (10 sessions)
Number of subjects: 40
Study 29227962 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 40
Study 29227962 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assisted structured aerobic exercise module
Number of subjects: 40
Study 29227962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 26432623 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-Bolus Insulin (B-BI)
Number of subjects: 64
Study 26432623 — intervention group
Group type: COMPARATOR
Intervention: Sliding Scale Insulin (SSI)
Number of subjects: 64
Study 26432623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (B-BI and SSI)
Number of subjects: 64